LLY
Eli Lilly and Company
LLY has the edge over TFX overall, supported by stronger modeled upside and stronger fundamentals.
TFX
Teleflex Incorporated
TFX trails on the overall score without a compensating advantage in the available component scores.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
TFX Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Healthy | |
| Under pressure | |
| Under pressure |
TFX's profitability is currently healthy, but its revenue, cash flow and balance sheet are under pressure.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
TFX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 15x | $153 | — |
| Current | 19x | $153 | — |
| Cheap | 28x | $227 | +48% |
| Fair | 34x | $279 | +82% |
| Expensive | 49x | $404 | +164% |
Historical ranges are pointers, not guarantees.
TFX has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over TFX on the outlook, with more favorable revenue expectations.
TFX Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Decline | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect TFX's earnings to grow and its profitability to improve, but its revenue to decline.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over TFX on earnings, with more consistent year-over-year improvement.
TFX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $9.93 | +21% |
| Q3 2026 | $8.23 | +$15.52 |
| Q2 2026 | -$23.29 | -640% |
| Q1 2026 | -$22.80 | -806% |
| Q4 2025 | -$20.55 | -1489% |
| Q3 2025 | -$7.29 | -245% |
| Q2 2025 | $4.31 | -23% |
| Q1 2025 | $3.23 | -48% |
| Q4 2024 | $1.48 | -80% |
TFX has returned to profit: it earned $8.23 per share over the past year, after losing money the year before. Its recent earnings include one-off gains.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over TFX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over TFX on profitability, with a higher operating margin.
TFX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $567.8M | -38% |
| Q2 2026 | $570.3M | -27% |
| Q1 2026 | $548.3M | -22% |
| Q4 2025 | $569M | -28% |
| Q3 2025 | $913M | +19% |
| Q2 2025 | $780.9M | +4.2% |
| Q1 2025 | $700.7M | -5% |
| Q4 2024 | $795.4M | +2.8% |
TFX's revenue has slid since its 2025 peak: $568M last quarter, down 38% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 19% | +63 points |
| Q2 2026 | 13% | -7.1 points |
| Q1 2026 | 3.7% | -14 points |
| Q4 2025 | 2.4% | +16 points |
| Q3 2025 | -45% | -64 points |
| Q2 2025 | 20% | +4.3 points |
| Q1 2025 | 18% | +19 points |
| Q4 2024 | -14% | -25 points |
TFX's operating margin was 19% last quarter, up 63 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over TFX on cash flow, with more consistent year-over-year improvement.
TFX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $74.7M | -4.1% |
| Q2 2026 | $77.9M | +$104.6M |
| Q1 2026 | $27.9M | -36% |
| Q4 2025 | -$92.9M | -154% |
| Q3 2025 | $77.8M | -63% |
| Q2 2025 | -$26.8M | -147% |
| Q1 2025 | $43.3M | -42% |
| Q4 2024 | $170.6M | +53% |
TFX still generates free cash flow, though less than at its 2024 peak: $87M over the past year.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has 893M diluted shares, down 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
TFX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -4.7% | -2M shares |
| 1 year | -5.9% | -2.6M shares |
| 3 years | -12% | -5.7M shares |
| 5 years | -12% | -5.8M shares |
| Available history | -12% | -5.5M shares |
TFX has the edge over LLY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $305M |
| Q2 2026 | $250M |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $300M |
| Q4 2024 | — |
TFX spent $555M buying back its own shares over the past year, up 85% from the year before.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY has the edge over TFX on leverage, with a lower net debt burden relative to earnings.
TFX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 3.6x | Elevated |
| Q4 2025 | 35.6x | High |
| Q3 2025 | 52.2x | High |
| Q2 2025 | 2.8x | Moderate |
| Q1 2025 | 2.9x | Moderate |
| Q4 2024 | 3.2x | Elevated |
| Q3 2024 | 2.5x | Moderate |
| Q2 2024 | 2.4x | Moderate |
TFX's net debt is about 3.6 years of its operating earnings (EBITDA), up from 2.9 years a year ago.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
TFX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.4 | Neutral |
| Stochastic | 85.3 | Overbought |
TFX's weekly RSI is 68 (neutral) and its Stochastic is 85 (overbought).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
TFX PE vs Healthcare Sector
| Metric | TFX | Sector median | Relative |
|---|---|---|---|
| PE | 19x | 26x | 28% below |
| PE % | 1 | 29 | 28 pts below |
TFX has the edge over LLY on valuation relative to its sector.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over TFX on trend strength, trading above more of its moving averages.
TFX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $135.2 | 13% above |
| 20 week MA | $135.0 | 13% above |
| 50 week MA | $125.9 | 22% above |
| 100 week MA | $130.4 | 17% above |
| 200 week MA | $179.2 | 15% below |
TFX has bounced recently, but its long-term trend is still down: it's above its 8-, 20-, 50- and 100-week averages, but 15% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over TFX on returns for 2026, with the stronger performance.
TFX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $372.0 | $405.1 | +8.9% |
| 2021 | $405.1 | $327.4 | -19% |
| 2022 | $327.4 | $248.8 | -24% |
| 2023 | $248.8 | $249.3 | +0.2% |
| 2024 | $249.3 | $179.5 | -28% |
| 2025 | $179.5 | $122.8 | -32% |
| 2026 YTD | $122.8 | $153.2 | +25% |
TFX has finished lower in four of the last six years. It's up 25% so far in 2026.